{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:16:49Z","timestamp":1791191809597,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.drugalcdep.2011.04.002","type":"journal-article","created":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T23:17:09Z","timestamp":1305933429000},"page":"265-273","source":"Crossref","is-referenced-by-count":60,"title":["Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing"],"prefix":"10.1016","volume":"118","author":[{"given":"Briony","family":"Larance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Winstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mattick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Horyniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0005","first-page":"427","article-title":"Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species","volume":"182","author":"Aboltins","year":"2005","journal-title":"MJA"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/09595230701829553","article-title":"Buprenorphine injection in Melbourne, Australia: an update","volume":"27","author":"Aitken","year":"2008","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.drugalcdep.2006.09.012","article-title":"Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users","volume":"88","author":"Alho","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0020","series-title":"National Opioid Pharmacotherapy Statistics Annual Data Collection: 2007 Report","author":"Australian Institute of Health and Welfare","year":"2008"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1360-0443.2007.01979.x","article-title":"A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence","volume":"102","author":"Bell","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0168-8278(00)00049-0","article-title":"Hepatitis after intravenous buprenorphine misuse in heroin addicts","volume":"34","author":"Berson","year":"2001","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1034\/j.1399-6576.2003.00201.x","article-title":"Serious overdoses involving buprenorphine in Helsinki","volume":"47","author":"Boyd","year":"2003","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0045","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/00952990802585406","article-title":"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine\/naloxone to the Malaysian market","volume":"35","author":"Bruce","year":"2009","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0050","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0055","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0060","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00213-005-0023-6","article-title":"Buprenorphine\/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers","volume":"181","author":"Comer","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.102.038141","article-title":"Self-administration of intravenous buprenorphine and the buprenorphine\/naloxone combination by recently detoxified heroin abusers","volume":"303","author":"Comer","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin users","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0075","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.drugalcdep.2009.08.011","article-title":"Monitoring risk: post marketing surveillance and signal detection","volume":"105","author":"Dart","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0080","first-page":"161","article-title":"Injection of medications used in opioid substitution treatment in Australia following the introduction of a mixed partial agonist\u2013antagonist opioid formulation","volume":"191","author":"Degenhardt","year":"2009","journal-title":"MJA"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0085","unstructured":"Degenhardt, L., Larance, B., Mathers, B., Azim, T., Kamarulzaman, A., Mattick, R.P., Panda, S., Toufik, A., Tyndall, M., Wiessing, L., Wodak, A., 2008. Benefits and risks of pharmaceutical opioids: essential treatment and diverted medication. A global review of availability, extra-medical use, injection and the association with HIV. Thematic paper undertaken on behalf of the Reference Group to the United Nations on HIV and Injecting Drug Use National Drug and Alcohol Research Centre, University of New South Wales, Sydney."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0095","series-title":"National Pharmacotherapy Policy for People Dependent on Opioids","author":"Department of Health and Ageing","year":"2007"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0100","unstructured":"Drugs and Poisons Regulation Group, 2006. In: Drugs Policy and Services Branch, Department of Health Services (Ed.), Policy for Maintenance Pharmacotherapy for Opioid Dependence. State of Victoria."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0105","series-title":"Policy Relating to the Use of Suboxone (Buprenorphine & Naloxone) and Subutex (Buprenorphine) in Opioid Dependence Treatment Programs","author":"Drugs of Dependence Unit","year":"2006"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0110","series-title":"Policy for Non-supervised Dosing of Methadone and Buprenorphine in Opioid Dependence Treatment Programs","author":"Drugs of Dependence Unit","year":"2007"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/0959523031000154508","article-title":"Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets","volume":"22","author":"Feeney","year":"2003","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.drugpo.2006.02.010","article-title":"The chronotope of the queue: methadone maintenance treatment and the production of time, space and subjects","volume":"17","author":"Fraser","year":"2006","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0130","series-title":"Methadone Maintenance Treatment in New South Wales and Victoria: Takeaways, Diversion and Other Key Issues","author":"Fraser","year":"2007"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0135","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.drugalcdep.2006.01.016","article-title":"Development of opioid formulations with limited diversion and abuse potential","volume":"83","author":"Fudala","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/09595230701373834","article-title":"Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records","volume":"26","author":"Gibson","year":"2007","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0145","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.drugalcdep.2006.02.008","article-title":"Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report","volume":"83","author":"Grudzinskas","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","article-title":"Heroin-assisted treatment for opioid dependence: randomised controlled trial","volume":"191","author":"Haasen","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(00)00126-5","article-title":"Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine","volume":"61","author":"Harris","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1526-4637.2006.00255.x","article-title":"Mechanisms of prescription drug diversion among drug-involved club- and street-based populations","volume":"8","author":"Inciardi","year":"2007","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1360-0443.2004.00958.x","article-title":"Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?","volume":"100","author":"Jenkinson","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0170","unstructured":"Larance, B., Degenhardt, L., Mattick, R.P., Lintzeris, N., Winstock, A. Definitions related to the use of pharmaceutical opioids: extra-medical use, diversion, non-adherence and aberrant drug behaviours. Drug Alcohol Rev., in press-a."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0175","doi-asserted-by":"crossref","unstructured":"Larance, B., Degenhardt, L., O\u2019Brien, S., Lintzeris, N., Winstock, A., Mattick, R.P., Bell, J., Ali, R. Prescribers\u2019 perceptions of the diversion and injection of medication by opioid substitution treatment patients. Drug Alcohol Rev., in press-b.","DOI":"10.1111\/j.1465-3362.2010.00274.x"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0180","series-title":"The Diversion and Injection of the Pharmaceutical Opioids used in Opioid Substitution Treatment: Findings from the Australian Post-marketing Surveillance Studies of Buprenorphine-naloxone","author":"Larance","year":"2009"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0185","series-title":"Investigation of Methadone Dosing in Victoria: Factors Influencing Dosing Levels","author":"Lintzeris","year":"2007"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0190","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1517\/14656560903213405","article-title":"The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence","volume":"10","author":"Mammen","year":"2009","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0195","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2","author":"Mattick","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0200","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1360-0443.2003.00348.x","article-title":"Methadone-related and heroin-related deaths among opiate users: methadone helps save lives","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0205","doi-asserted-by":"crossref","unstructured":"Mattick, R.P., Kimber, J., Breen, C., Davoli, M., 2008. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Reviews 2008 2: Art. No.: CD002207. doi:10.1002\/14651858.CD002207.pub3.","DOI":"10.1002\/14651858.CD002207.pub3"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0210","series-title":"Methadone Maintenance Treatment and Other Opioid Replacement Therapies","article-title":"The effectiveness of other opioid replacement therapies: LAAM, heroin, buprenorphine, naltrexone and injectable maintenance","author":"Mattick","year":"1998"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0215","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.drugalcdep.2009.08.003","article-title":"Case histories in pharmaceutical risk management","volume":"105","author":"McCormick","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0220","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0376-8716(03)00057-7","article-title":"Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?","volume":"70","author":"Mendelson","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0225","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0006-3223(96)00266-1","article-title":"Buprenorphine and naloxone interactions in methadone maintenance patients","volume":"41","author":"Mendelson","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0230","unstructured":"Mental Health and Drug and Alcohol Office, 2006. In: NSW Department of Health (Ed.), New South Wales Opioid Treatment Program: Clinical Guidelines for Methadone and Buprenorphine Treatment of Opioid Dependence."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.drugalcdep.2003.12.008","article-title":"A dose\u2013effect study of repeated administration of buprenorphine\/naloxone on performance in opioid-dependent volunteers","volume":"74","author":"Mintzer","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0240","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550880903014767","article-title":"Diversion of buprenorphine\/naloxone coformulated tablets in a region with high prescribing prevalence","volume":"28","author":"Monte","year":"2009","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0245","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/09595230601146645","article-title":"Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified","volume":"26","author":"Nielsen","year":"2007","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0250","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1360-0443.2004.00790.x","article-title":"A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 25 methadone-associated deaths","volume":"99","author":"Pirnay","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0376-8716(93)90036-P","article-title":"The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand","volume":"33","author":"Robinson","year":"1993","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2007.04.006","article-title":"Sublingual buprenorphine\/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone","volume":"90","author":"Rosado","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugalcdep.2008.03.025","article-title":"Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management","volume":"97","author":"Roux","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0270","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.addbeh.2008.07.018","article-title":"Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France","volume":"33","author":"Roux","year":"2008","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0275","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.drugalcdep.2005.11.028","article-title":"Abuse deterrent formulations and the Controlled Substances Act (CSA)","volume":"83","author":"Sapienza","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0280","series-title":"CPDD Annual Meeting","article-title":"Post-marketing surveillance of Suboxone and Subutex diversion","author":"Schuster","year":"2005"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0285","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.drugalcdep.2006.01.006","article-title":"History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs","volume":"83","author":"Schuster","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0290","series-title":"Australian Drug Trends 2008: Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series","author":"Stafford","year":"2009"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0295","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s002130050066","article-title":"Effects of buprenorphine versus buprenorphine\/naloxone tablets in non-dependent opioid abusers","volume":"148","author":"Strain","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0300","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(10)60349-2","article-title":"Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial","volume":"375","author":"Strang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugalcdep.2010.03.014","article-title":"Injection of buprenorphine and buprenorphine\/naloxone tablets in Malaysia","volume":"111","author":"Vicknasingam","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0376-8716(92)90061-G","article-title":"Buprenorphine alone and in combination with naloxone in non-dependent humans","volume":"30","author":"Weinhold","year":"1992","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0315","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/02791072.2004.10400047","article-title":"Buprenorphine in the treatment of opiate dependence: Its pharmacology and social context of use in the U.S.","volume":"36","author":"Wesson","year":"2004","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0320","first-page":"395","article-title":"Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence","volume":"15","author":"Winstock","year":"2008","journal-title":"Drugs: Educ. Prev. Policy"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0325","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1360-0443.2009.02774.x","article-title":"Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia","volume":"105","author":"Winstock","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0330","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/10550880802545036","article-title":"Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics","volume":"28","author":"Winstock","year":"2009","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0335","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.drugpo.2007.03.002","article-title":"Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia","volume":"19","author":"Winstock","year":"2008","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0340","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/10550880903028841","article-title":"What is diversion of supervised buprenorphine and how common is it?","volume":"28","author":"Winstock","year":"2009","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0345","series-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.drugalcdep.2011.04.002_bib0350","series-title":"Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV\/AIDS Prevention","author":"World Health Organization\/United Nations Office on Drugs and Crime\/Joint United Nations Programme on HIV\/AIDS","year":"2004"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161100158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037687161100158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T14:00:25Z","timestamp":1543759225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037687161100158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":70,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S037687161100158X"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.04.002","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}